MLR Review in the AI Era: 4 Scenarios and 4 Stakeholders

MLR review sits close to the market.

It is where scientific claims, commercial messages, legal boundaries, regulatory expectations, medical evidence, and patient-facing context meet in one workflow.

That is why MLR review is often underestimated. It can look like a document approval process from the outside. In practice, it is one of the most risk-dense parts of post-market medical content operations.

Every efficacy claim, safety statement, chart, reference, disclaimer, patient education paragraph, HCP slide, and localized adaptation can create a review question.

As AI changes how medical content materials are created, adapted, and reused, the MLR workflow needs to change as well.

The goal is not to replace reviewers. The goal is to move repetitive checking earlier, make risks easier to see, and let accountable reviewers spend more time on the decisions that require professional judgment.

The paradox: more content, same review pressure

Medical content teams are producing more assets across more channels.

Core decks become local presentations. Congress materials become follow-up content. HCP education assets become field tools. Patient education materials are adapted across regions. Approved slides are reused, revised, and recombined.

At the same time, review capacity rarely grows at the same rate.

This creates a familiar tension:

• Content teams need speed.
• Medical reviewers need scientific accuracy.
• Legal and compliance teams need risk control.
• Regulatory teams need claim discipline.
• Local markets need adaptation.
• External partners need clearer guidance.

When all of this runs through manual review alone, the workflow becomes fragile. High-risk content may not receive enough attention, while low-risk updates can consume expert time. Reviewers are asked to perform both repetitive checking and nuanced interpretation at the same time.

AI-assisted review can help, but only if it is placed in the right part of the workflow.

Scenario 1: Pre-checking before formal submission

The first practical scenario is pre-checking before a material enters formal MLR review.

This does not mean approving content automatically. It means scanning the material earlier for routine issues that slow down review:

• missing safety language
• incomplete disclaimers
• inconsistent terminology
• potential off-label wording
• unsupported claim candidates
• privacy-sensitive fields
• slide changes from approved versions

When these issues are detected before formal submission, teams can fix routine problems earlier and avoid sending avoidable defects into the review queue.

The value is not just speed. It is better use of expert attention.

Reviewers should not spend most of their time finding missing footnotes, repeated wording deviations, or obvious version conflicts. They should spend more time judging scientific context, evidence interpretation, market nuance, and risk trade-offs.

Scenario 2: Claim traceability and reference linking

One of the most time-consuming parts of MLR review is checking whether a claim is supported by the right source.

This is difficult because claims do not stay still.

A statement may begin in a label, a publication, a core claim library, or a previously approved material. Then it may be shortened, translated, localized, reformatted, or placed next to a chart. Each adaptation can change how the claim is understood.

AI-assisted review can help by comparing statements against approved sources, linking claim candidates to references, and flagging places where the wording or context appears to drift.

This is especially useful when teams need to review:

• reused slides
• adapted claims
• scientific statements across versions
• citations and footnotes
• chart captions and explanatory text
• claims translated into local language

The output should be human-reviewable. A reviewer needs to see what was flagged, why it was flagged, and which source or prior version is relevant.

Traceability is not only about finding a reference. It is about making the review decision easier to explain.

Scenario 3: Multi-market localization review

For multinational life sciences teams, localization is not just translation.

The same global master material may need to be adapted for different markets, channels, product stages, and audience types. A statement that is acceptable in one market may require additional qualification in another. A disclaimer may be mandatory in one context and irrelevant in another. A patient-facing explanation may need a different standard than an HCP-facing slide.

Manual localization review can work for a small number of assets. But at scale, teams need a more structured way to compare local versions against both global intent and local requirements.

AI-assisted review can support localization by:

• comparing local materials against global masters
• identifying added, removed, or changed claims
• checking whether required disclaimers remain present
• highlighting local wording that may alter scientific meaning
• routing market-specific questions to the right reviewer

Again, the goal is not to make the market decision automatic. It is to help local and global teams see where the decision points are.

Scenario 4: Risk routing and digital review traces

Not all review issues require the same attention.

A missing reference, a new efficacy claim, a privacy-sensitive screenshot, a changed safety statement, and a formatting error should not be treated as the same kind of problem.

AI-assisted review can help classify issues by risk type, severity, page location, and likely owner. It can also create a more consistent record of what was flagged, what evidence was shown, and how the issue was resolved.

This matters for auditability.

MLR review is not only about reaching a decision. It is also about being able to explain how that decision was reached later.

A useful review system should therefore support:

• issue location
• risk category
• source evidence
• reviewer owner
• decision status
• resolution notes
• version history

This creates a digital review trace that supports both operational efficiency and governance.

Stakeholder 1: Medical Affairs

Medical Affairs teams are responsible for scientific integrity.

For them, AI-assisted review is valuable when it helps detect whether claims remain evidence-aligned and whether scientific nuance has been lost during adaptation.

The benefit is not less medical judgment. It is better preparation for medical judgment.

When the system surfaces claim drift, reference mismatch, or missing context earlier, medical reviewers can focus on the interpretation questions that matter.

Stakeholder 2: Marketing and commercial teams

Marketing and commercial teams need content to move at the pace of campaigns, field needs, and market opportunities.

But speed without review readiness creates rework. A deck that enters MLR with avoidable issues may come back with repeated comments, delaying launch and frustrating everyone involved.

AI-assisted pre-review can help commercial teams submit cleaner materials:

• fewer avoidable defects
• clearer claim support
• better version discipline
• earlier visibility into high-risk sections

This makes speed more sustainable because it reduces downstream review friction.

Stakeholder 3: Legal, regulatory, and compliance teams

Legal, regulatory, and compliance teams carry responsibility for risk control.

Their challenge is not only finding problems. It is prioritizing which problems deserve deep attention.

AI-assisted review can help by separating routine issues from higher-risk decisions, surfacing evidence, and routing issues to the right owner. This allows expert teams to spend less time on administrative checking and more time on regulatory interpretation, policy alignment, and edge cases.

Stakeholder 4: MedComm agencies and external partners

External partners often sit between strategy and execution.

They prepare drafts, adapt materials, manage versions, and respond to review comments. Without a shared review logic, small inconsistencies can multiply across projects and markets.

A unified AI-assisted review layer can help agencies and partners understand what the client expects before formal submission. It can reduce rework, standardize claim management, and make collaboration less dependent on informal memory.

The human role becomes more important, not less

AI can support pre-checking, traceability, localization comparison, and risk routing.

But it cannot own the final judgment.

Contextual interpretation of scientific evidence, understanding of regulatory intent, and risk assessment in gray areas still require qualified human reviewers.

The right model is not replacement. It is better allocation of attention.

AI handles repetitive, rule-based, high-frequency checks. Human reviewers handle decisions that require context, accountability, and professional judgment.

That is how MLR review becomes faster without becoming weaker.